Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Aim(s): The aim of the study was to estimate the survival of large cell neuroendocrine lung cancer and combined LCNEC and identify prognostic factors of OS and PFS.
Materials and methods: All patients in stage I-IV LCNEC and combined LCNEC recorded between 2002-2018 were included. OS and PFS were estimated by Kaplan Meier method. Uni- and multivariable analysis was estimated by Cox-regression model. A p value <0.05 was considered to be significant.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.